EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...
The Gonzales Lab at UNR Med, led by Albert Gonzales, Ph.D., assistant professor of physiology and cell biology, spearheaded ...
After repeatedly wowing investors, Roche’s star eye med Vabysmo collected more than $4 billion in sales during its third year on the market. | After repeatedly wowing investors, Roche’s star eye med ...
Leerink Partners analyst Marc Goodman has maintained their bullish stance on OPT stock, giving a Buy rating yesterday.Invest with Confidence: ...
Discover the importance of vision, genetic eye disorders, and RNA-based therapies for precision treatment in India and ...
SBL03 was formulated as an ophthalmic gel for non-invasive topical delivery. Its unique ability to infiltrate eye tissues effectively and protect ret ...
LifeArc Ventures, which invests in innovative early-stage life science companies as part of LifeArc, today announced substantial progress in 2024, with three new investments, several follow-on ...
Eye Care Supplement MarketThe global eye care supplement market is on the cusp of significant expansion, with leading market analysis authority Future Market Insights (FMI) predicting a valuation of ...
What is red light therapy? Treatment with red light therapy involves exposure to red light at a very low dose in a hospital or clinic. It’s also called low-power laser therapy, soft laser therapy, ...
Brookline Capital Management upgraded shares of Cognition Therapeutics (NASDAQ:CGTX – Free Report) to a strong-buy rating in a report released on Monday morning,Zacks.com reports. Brookline Capital ...
H.C. Wainwright initiated coverage on Surrozen Inc. (NASDAQ:SRZN) with a Buy rating and established a price target of $32.00. The clinical-stage biotechnology company, currently valued at ...
Group sales grew by 7%1 at constant exchange rates (CER; 3% in CHF), driven by strong demand for both medicines and diagnostics.Excluding COVID-19, Group sales increased by 9%.